Galapagos wins 2011 Scrip Award for Biotech Company of the Year
Galapagos NV announced that it won the prestigious Scrip Award for Biotech Company of the Year at last night's ceremony in London. The award recognizes the biotech company that has achieved the most in the 12-month period from June 2010 to May 2011.
The international jury, which consisted of sixteen industry experts, selected Galapagos as the Biotech Company of the Year from a group of six finalists. The award criteria included: clinical progress, significant alliances and licensing deals, fund raising, strong management and applying a proprietary technology to address unmet medical needs.
Galapagos was awarded the prize based on its transformation into a sustainably profitable biotech with a solid pipeline of novel mode-of-action drug candidates. Galapagos has achieved this self reliance by successfully executing on a hybrid business model: combining profitable fee-for-service based service operations with an internal R&D division that has established six risk/reward sharing alliances with the world's top pharma companies.
"We are pleased to have won the 2011 Scrip Award for Biotech Company of the Year, which recognizes the impact of Galapagos' proprietary technology and successful hybrid business model," said Onno van de Stolpe, CEO of Galapagos. "Furthermore, this award recognizes our transition to a more mature company with a full-fledged development pipeline."
Other news from the department business & finance
